On Jun. 8, 2020, Eli Lilly announced its partner Junshi Biosciences had dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19. The investigational medicine, referred to as JS016, was being co-developed by Junshi Biosciences and Lilly, with Junshi Biosciences leading development in Greater China. Lilly has exclusive rights in the rest of the world.